APO Research
Talk to an analyst

APO RESEARCH · REPORT

Intravenous Immunoglobulin(IVIg) Therapy

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Intravenous Immunoglobulin(IVIg) Therapy Market Outlook and Growth Opportunities 2026

30 December 2025202 pages

Choose your research edition.

Industry ResearchIntravenous Immunoglobulin(IVIg) Therapy Industry Research Report 2026142 pages · $2,950 USDIndustry Growth & TrendsGlobal Intravenous Immunoglobulin(IVIg) Therapy Industry Growth and Trends Forecast to 2032127 pages · $3,450 USDMarket StructureGlobal Intravenous Immunoglobulin(IVIg) Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Intravenous Immunoglobulin(IVIg) Therapy Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Intravenous Immunoglobulin(IVIg) Therapy Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Intravenous Immunoglobulin(IVIg) Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Intravenous Immunoglobulin(IVIg) Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Intravenous Immunoglobulin(IVIg) Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Intravenous Immunoglobulin(IVIg) Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Intravenous Immunoglobulin(IVIg) Therapy market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Intravenous Immunoglobulin(IVIg) Therapy market include TEIJIN LIMITED, Baxter, Biotest, Boya-Bio, CNBG, CSL Plasma, Grifols, Kamada and Kedrion, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Intravenous Immunoglobulin(IVIg) Therapy market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Intravenous Immunoglobulin(IVIg) Therapy and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Intravenous Immunoglobulin(IVIg) Therapy sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Intravenous Immunoglobulin(IVIg) Therapy market size, projected growth trends, production technologies, key applications, and end-use industries.

Intravenous Immunoglobulin(IVIg) Therapy Segment by Company

TEIJIN LIMITED

Baxter

Biotest

Boya-Bio

CNBG

CSL Plasma

Grifols

Kamada

Kedrion

LFB Group

Nanyue Biopharming

Octapharma

Sinopharm

Beijing Tiantan Biological Products

Guangdong Shuagnlin Bio-pharmacy

Hualan Bio

Shanghai RAAS

Weiguang Biological

Taibang Biologic Group

Takeda

Intravenous Immunoglobulin(IVIg) Therapy Segment by Type

5g/100ml

2.5g/50ml

1g/20ml

10g/200ml

1.25g/25ml

Others

Intravenous Immunoglobulin(IVIg) Therapy Segment by Application

Autoimmune Disease

Immunodeficiency

Acute Infection

Others

Intravenous Immunoglobulin(IVIg) Therapy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Intravenous Immunoglobulin(IVIg) Therapy status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Intravenous Immunoglobulin(IVIg) Therapy market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Intravenous Immunoglobulin(IVIg) Therapy significant trends, drivers, influence factors in global and regions.

6. To analyze Intravenous Immunoglobulin(IVIg) Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Intravenous Immunoglobulin(IVIg) Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Intravenous Immunoglobulin(IVIg) Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Intravenous Immunoglobulin(IVIg) Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Intravenous Immunoglobulin(IVIg) Therapy market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Intravenous Immunoglobulin(IVIg) Therapy industry.

Chapter 3: Detailed analysis of Intravenous Immunoglobulin(IVIg) Therapy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Intravenous Immunoglobulin(IVIg) Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Intravenous Immunoglobulin(IVIg) Therapy in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Intravenous Immunoglobulin(IVIg) Therapy Industry Trends Table 2. Intravenous Immunoglobulin(IVIg) Therapy Industry Drivers Table 3. Intravenous Immunoglobulin(IVIg) Therapy Industry Opportunities and Challenges Table 4. Intravenous Immunoglobulin(IVIg) Therapy Industry Restraints Table 5. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue Share by Company (2021-2026) Table 7. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume Share by Company (2021-2026) Table 9. Global Intravenous Immunoglobulin(IVIg) Therapy Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Intravenous Immunoglobulin(IVIg) Therapy Company Ranking, (2024-2026) & (USD Million) Table 11. Global Intravenous Immunoglobulin(IVIg) Therapy Key Company Manufacturing Base & Headquarters Table 12. Global Intravenous Immunoglobulin(IVIg) Therapy Company, Product Type & Application Table 13. Global Intravenous Immunoglobulin(IVIg) Therapy Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Intravenous Immunoglobulin(IVIg) Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 5g/100ml Table 18. Significant Companies of 2.5g/50ml Table 19. Significant Companies of 1g/20ml Table 20. Significant Companies of 10g/200ml Table 21. Significant Companies of 1.25g/25ml Table 22. Significant Companies of Others Table 23. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume by Type (2021-2026) & (K Units) Table 25. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume by Type (2027-2032) & (K Units) Table 26. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume Share by Type (2021-2026) Table 27. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume Share by Type (2027-2032) Table 28. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type (2021-2026) Table 32. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Autoimmune Disease Table 34. Significant Companies of Immunodeficiency Table 35. Significant Companies of Acute Infection Table 36. Significant Companies of Others Table 37. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume by Application (2021-2026) & (K Units) Table 39. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume by Application (2027-2032) & (K Units) Table 40. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume Share by Application (2021-2026) Table 41. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume Share by Application (2027-2032) Table 42. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application (2021-2026) Table 46. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application (2027-2032) Table 47. Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 48. Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Region (2021-2026) & (K Units) Table 49. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Region (2021-2026) Table 50. Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Region (2027-2032) & (K Units) Table 51. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Region (2027-2032) Table 52. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Region (2021-2026) Table 55. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Region (2027-2032) Table 57. Global Intravenous Immunoglobulin(IVIg) Therapy Market Average Price (US$/Unit) by Region (2021-2026) Table 58. Global Intravenous Immunoglobulin(IVIg) Therapy Market Average Price (US$/Unit) by Region (2027-2032) Table 59. Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2021-2026) & (K Units) Table 62. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Country (2021-2026) Table 63. Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2027-2032) & (K Units) Table 64. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Country (2027-2032) Table 65. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value Market Share by Country (2021-2026) Table 67. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value Market Share by Country (2027-2032) Table 69. TEIJIN LIMITED Company Information Table 70. TEIJIN LIMITED Business Overview Table 71. TEIJIN LIMITED Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. TEIJIN LIMITED Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 73. TEIJIN LIMITED Recent Development Table 74. Baxter Company Information Table 75. Baxter Business Overview Table 76. Baxter Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Baxter Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 78. Baxter Recent Development Table 79. Biotest Company Information Table 80. Biotest Business Overview Table 81. Biotest Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Biotest Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 83. Biotest Recent Development Table 84. Boya-Bio Company Information Table 85. Boya-Bio Business Overview Table 86. Boya-Bio Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Boya-Bio Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 88. Boya-Bio Recent Development Table 89. CNBG Company Information Table 90. CNBG Business Overview Table 91. CNBG Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. CNBG Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 93. CNBG Recent Development Table 94. CSL Plasma Company Information Table 95. CSL Plasma Business Overview Table 96. CSL Plasma Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. CSL Plasma Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 98. CSL Plasma Recent Development Table 99. Grifols Company Information Table 100. Grifols Business Overview Table 101. Grifols Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Grifols Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 103. Grifols Recent Development Table 104. Kamada Company Information Table 105. Kamada Business Overview Table 106. Kamada Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Kamada Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 108. Kamada Recent Development Table 109. Kedrion Company Information Table 110. Kedrion Business Overview Table 111. Kedrion Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Kedrion Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 113. Kedrion Recent Development Table 114. LFB Group Company Information Table 115. LFB Group Business Overview Table 116. LFB Group Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. LFB Group Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 118. LFB Group Recent Development Table 119. Nanyue Biopharming Company Information Table 120. Nanyue Biopharming Business Overview Table 121. Nanyue Biopharming Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Nanyue Biopharming Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 123. Nanyue Biopharming Recent Development Table 124. Octapharma Company Information Table 125. Octapharma Business Overview Table 126. Octapharma Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Octapharma Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 128. Octapharma Recent Development Table 129. Sinopharm Company Information Table 130. Sinopharm Business Overview Table 131. Sinopharm Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Sinopharm Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 133. Sinopharm Recent Development Table 134. Beijing Tiantan Biological Products Company Information Table 135. Beijing Tiantan Biological Products Business Overview Table 136. Beijing Tiantan Biological Products Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Beijing Tiantan Biological Products Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 138. Beijing Tiantan Biological Products Recent Development Table 139. Guangdong Shuagnlin Bio-pharmacy Company Information Table 140. Guangdong Shuagnlin Bio-pharmacy Business Overview Table 141. Guangdong Shuagnlin Bio-pharmacy Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Guangdong Shuagnlin Bio-pharmacy Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 143. Guangdong Shuagnlin Bio-pharmacy Recent Development Table 144. Hualan Bio Company Information Table 145. Hualan Bio Business Overview Table 146. Hualan Bio Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. Hualan Bio Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 148. Hualan Bio Recent Development Table 149. Shanghai RAAS Company Information Table 150. Shanghai RAAS Business Overview Table 151. Shanghai RAAS Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 152. Shanghai RAAS Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 153. Shanghai RAAS Recent Development Table 154. Weiguang Biological Company Information Table 155. Weiguang Biological Business Overview Table 156. Weiguang Biological Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 157. Weiguang Biological Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 158. Weiguang Biological Recent Development Table 159. Taibang Biologic Group Company Information Table 160. Taibang Biologic Group Business Overview Table 161. Taibang Biologic Group Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 162. Taibang Biologic Group Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 163. Taibang Biologic Group Recent Development Table 164. Takeda Company Information Table 165. Takeda Business Overview Table 166. Takeda Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 167. Takeda Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 168. Takeda Recent Development Table 169. Key Raw Materials Table 170. Raw Materials Key Suppliers Table 171. Intravenous Immunoglobulin(IVIg) Therapy Distributors List Table 172. Intravenous Immunoglobulin(IVIg) Therapy Customers List Table 173. Research Programs/Design for This Report Table 174. Authors List of This Report Table 175. Secondary Sources Table 176. Primary Sources List of Figures Figure 1. Intravenous Immunoglobulin(IVIg) Therapy Product Image Figure 2. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value (2021-2032) & (US$ Million) Figure 4. Global Intravenous Immunoglobulin(IVIg) Therapy Sales (2021-2032) & (K Units) Figure 5. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Intravenous Immunoglobulin(IVIg) Therapy Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 5g/100ml Image Figure 10. 2.5g/50ml Image Figure 11. 1g/20ml Image Figure 12. 10g/200ml Image Figure 13. 1.25g/25ml Image Figure 14. Others Image Figure 15. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume Share by Type (2021-2032) Figure 18. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type (2021-2032) Figure 21. Autoimmune Disease Image Figure 22. Immunodeficiency Image Figure 23. Acute Infection Image Figure 24. Others Image Figure 25. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume Share by Application (2021-2032) Figure 28. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application (2021-2032) Figure 31. Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 32. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Intravenous Immunoglobulin(IVIg) Therapy Sales Value (2021-2032) & (US$ Million) Figure 36. North America Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe Intravenous Immunoglobulin(IVIg) Therapy Sales Value (2021-2032) & (US$ Million) Figure 38. Europe Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific Intravenous Immunoglobulin(IVIg) Therapy Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America Intravenous Immunoglobulin(IVIg) Therapy Sales Value (2021-2032) & (US$ Million) Figure 42. South America Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa Intravenous Immunoglobulin(IVIg) Therapy Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Intravenous Immunoglobulin(IVIg) Therapy Value Chain Figure 130. Manufacturing Cost Structure Figure 131. Intravenous Immunoglobulin(IVIg) Therapy Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • 5g/100ml
  • 2.5g/50ml
  • 1g/20ml
  • 10g/200ml
  • 1.25g/25ml
  • Others
Applications
  • Autoimmune Disease
  • Immunodeficiency
  • Acute Infection
  • Others
Companies covered
  • TEIJIN LIMITED
  • Baxter
  • Biotest
  • Boya-Bio
  • CNBG
  • CSL Plasma
  • Grifols
  • Kamada
  • Kedrion
  • LFB Group
  • Nanyue Biopharming
  • Octapharma
  • Sinopharm
  • Beijing Tiantan Biological Products
  • Guangdong Shuagnlin Bio-pharmacy
  • Hualan Bio
  • Shanghai RAAS
  • Weiguang Biological
  • Taibang Biologic Group
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value (2021-2032)
  4. 1.2.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume (2021-2032)
  5. 1.2.3 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Intravenous Immunoglobulin(IVIg) Therapy Market Dynamics
  1. 2.1 Intravenous Immunoglobulin(IVIg) Therapy Industry Trends
  2. 2.2 Intravenous Immunoglobulin(IVIg) Therapy Industry Drivers
  3. 2.3 Intravenous Immunoglobulin(IVIg) Therapy Industry Opportunities and Challenges
  4. 2.4 Intravenous Immunoglobulin(IVIg) Therapy Industry Restraints
3 Intravenous Immunoglobulin(IVIg) Therapy Market by Company
  1. 3.1 Global Intravenous Immunoglobulin(IVIg) Therapy Company Revenue Ranking in 2025
  2. 3.2 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Company (2021-2026)
  3. 3.3 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume by Company (2021-2026)
  4. 3.4 Global Intravenous Immunoglobulin(IVIg) Therapy Average Price by Company (2021-2026)
  5. 3.5 Global Intravenous Immunoglobulin(IVIg) Therapy Company Ranking (2024-2026)
  6. 3.6 Global Intravenous Immunoglobulin(IVIg) Therapy Company Manufacturing Base and Headquarters
  7. 3.7 Global Intravenous Immunoglobulin(IVIg) Therapy Company Product Type and Application
  8. 3.8 Global Intravenous Immunoglobulin(IVIg) Therapy Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Intravenous Immunoglobulin(IVIg) Therapy Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Intravenous Immunoglobulin(IVIg) Therapy Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Intravenous Immunoglobulin(IVIg) Therapy Market by Type
  1. 4.1 Intravenous Immunoglobulin(IVIg) Therapy Type Introduction
  2. 4.1.1 5g/100ml
  3. 4.1.2 2.5g/50ml
  4. 4.1.3 1g/20ml
  5. 4.1.4 10g/200ml
  6. 4.1.5 1.25g/25ml
  7. 4.1.6 Others
  8. 4.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume by Type
  9. 4.2.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Type
  13. 4.3.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Type (2021-2032)
  15. 4.3.3 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type (2021-2032)
5 Intravenous Immunoglobulin(IVIg) Therapy Market by Application
  1. 5.1 Intravenous Immunoglobulin(IVIg) Therapy Application Introduction
  2. 5.1.1 Autoimmune Disease
  3. 5.1.2 Immunodeficiency
  4. 5.1.3 Acute Infection
  5. 5.1.4 Others
  6. 5.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume by Application
  7. 5.2.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Application
  11. 5.3.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Application (2021-2032)
  13. 5.3.3 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application (2021-2032)
6 Intravenous Immunoglobulin(IVIg) Therapy Regional Sales and Value Analysis
  1. 6.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Region (2021-2032)
  3. 6.2.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Region: 2021-2026
  4. 6.2.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Region (2027-2032)
  5. 6.3 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Region (2021-2032)
  7. 6.4.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Region: 2021-2026
  8. 6.4.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Region (2027-2032)
  9. 6.5 Global Intravenous Immunoglobulin(IVIg) Therapy Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Intravenous Immunoglobulin(IVIg) Therapy Sales Value (2021-2032)
  12. 6.6.2 North America Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Intravenous Immunoglobulin(IVIg) Therapy Sales Value (2021-2032)
  15. 6.7.2 Europe Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Intravenous Immunoglobulin(IVIg) Therapy Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Intravenous Immunoglobulin(IVIg) Therapy Sales Value (2021-2032)
  21. 6.9.2 South America Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Intravenous Immunoglobulin(IVIg) Therapy Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Country, 2025 VS 2032
7 Intravenous Immunoglobulin(IVIg) Therapy Country-level Sales and Value Analysis
  1. 7.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2021-2032)
  4. 7.3.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2021-2026)
  5. 7.3.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2027-2032)
  6. 7.4 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Country (2021-2032)
  7. 7.4.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Country (2021-2026)
  8. 7.4.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Intravenous Immunoglobulin(IVIg) Therapy Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Intravenous Immunoglobulin(IVIg) Therapy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 TEIJIN LIMITED
  2. 8.1.1 TEIJIN LIMITED Company Information
  3. 8.1.2 TEIJIN LIMITED Business Overview
  4. 8.1.3 TEIJIN LIMITED Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 TEIJIN LIMITED Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  6. 8.1.5 TEIJIN LIMITED Recent Developments
  7. 8.2 Baxter
  8. 8.2.1 Baxter Company Information
  9. 8.2.2 Baxter Business Overview
  10. 8.2.3 Baxter Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Baxter Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  12. 8.2.5 Baxter Recent Developments
  13. 8.3 Biotest
  14. 8.3.1 Biotest Company Information
  15. 8.3.2 Biotest Business Overview
  16. 8.3.3 Biotest Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Biotest Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  18. 8.3.5 Biotest Recent Developments
  19. 8.4 Boya-Bio
  20. 8.4.1 Boya-Bio Company Information
  21. 8.4.2 Boya-Bio Business Overview
  22. 8.4.3 Boya-Bio Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Boya-Bio Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  24. 8.4.5 Boya-Bio Recent Developments
  25. 8.5 CNBG
  26. 8.5.1 CNBG Company Information
  27. 8.5.2 CNBG Business Overview
  28. 8.5.3 CNBG Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 CNBG Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  30. 8.5.5 CNBG Recent Developments
  31. 8.6 CSL Plasma
  32. 8.6.1 CSL Plasma Company Information
  33. 8.6.2 CSL Plasma Business Overview
  34. 8.6.3 CSL Plasma Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 CSL Plasma Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  36. 8.6.5 CSL Plasma Recent Developments
  37. 8.7 Grifols
  38. 8.7.1 Grifols Company Information
  39. 8.7.2 Grifols Business Overview
  40. 8.7.3 Grifols Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Grifols Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  42. 8.7.5 Grifols Recent Developments
  43. 8.8 Kamada
  44. 8.8.1 Kamada Company Information
  45. 8.8.2 Kamada Business Overview
  46. 8.8.3 Kamada Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Kamada Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  48. 8.8.5 Kamada Recent Developments
  49. 8.9 Kedrion
  50. 8.9.1 Kedrion Company Information
  51. 8.9.2 Kedrion Business Overview
  52. 8.9.3 Kedrion Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Kedrion Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  54. 8.9.5 Kedrion Recent Developments
  55. 8.10 LFB Group
  56. 8.10.1 LFB Group Company Information
  57. 8.10.2 LFB Group Business Overview
  58. 8.10.3 LFB Group Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 LFB Group Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  60. 8.10.5 LFB Group Recent Developments
  61. 8.11 Nanyue Biopharming
  62. 8.11.1 Nanyue Biopharming Company Information
  63. 8.11.2 Nanyue Biopharming Business Overview
  64. 8.11.3 Nanyue Biopharming Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Nanyue Biopharming Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  66. 8.11.5 Nanyue Biopharming Recent Developments
  67. 8.12 Octapharma
  68. 8.12.1 Octapharma Company Information
  69. 8.12.2 Octapharma Business Overview
  70. 8.12.3 Octapharma Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Octapharma Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  72. 8.12.5 Octapharma Recent Developments
  73. 8.13 Sinopharm
  74. 8.13.1 Sinopharm Company Information
  75. 8.13.2 Sinopharm Business Overview
  76. 8.13.3 Sinopharm Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Sinopharm Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  78. 8.13.5 Sinopharm Recent Developments
  79. 8.14 Beijing Tiantan Biological Products
  80. 8.14.1 Beijing Tiantan Biological Products Company Information
  81. 8.14.2 Beijing Tiantan Biological Products Business Overview
  82. 8.14.3 Beijing Tiantan Biological Products Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Beijing Tiantan Biological Products Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  84. 8.14.5 Beijing Tiantan Biological Products Recent Developments
  85. 8.15 Guangdong Shuagnlin Bio-pharmacy
  86. 8.15.1 Guangdong Shuagnlin Bio-pharmacy Company Information
  87. 8.15.2 Guangdong Shuagnlin Bio-pharmacy Business Overview
  88. 8.15.3 Guangdong Shuagnlin Bio-pharmacy Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Guangdong Shuagnlin Bio-pharmacy Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  90. 8.15.5 Guangdong Shuagnlin Bio-pharmacy Recent Developments
  91. 8.16 Hualan Bio
  92. 8.16.1 Hualan Bio Company Information
  93. 8.16.2 Hualan Bio Business Overview
  94. 8.16.3 Hualan Bio Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Hualan Bio Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  96. 8.16.5 Hualan Bio Recent Developments
  97. 8.17 Shanghai RAAS
  98. 8.17.1 Shanghai RAAS Company Information
  99. 8.17.2 Shanghai RAAS Business Overview
  100. 8.17.3 Shanghai RAAS Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Shanghai RAAS Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  102. 8.17.5 Shanghai RAAS Recent Developments
  103. 8.18 Weiguang Biological
  104. 8.18.1 Weiguang Biological Company Information
  105. 8.18.2 Weiguang Biological Business Overview
  106. 8.18.3 Weiguang Biological Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Weiguang Biological Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  108. 8.18.5 Weiguang Biological Recent Developments
  109. 8.19 Taibang Biologic Group
  110. 8.19.1 Taibang Biologic Group Company Information
  111. 8.19.2 Taibang Biologic Group Business Overview
  112. 8.19.3 Taibang Biologic Group Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Taibang Biologic Group Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  114. 8.19.5 Taibang Biologic Group Recent Developments
  115. 8.20 Takeda
  116. 8.20.1 Takeda Company Information
  117. 8.20.2 Takeda Business Overview
  118. 8.20.3 Takeda Intravenous Immunoglobulin(IVIg) Therapy Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Takeda Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  120. 8.20.5 Takeda Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Intravenous Immunoglobulin(IVIg) Therapy Value Chain Analysis
  2. 9.1.1 Intravenous Immunoglobulin(IVIg) Therapy Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Intravenous Immunoglobulin(IVIg) Therapy Sales Mode & Process
  6. 9.2 Intravenous Immunoglobulin(IVIg) Therapy Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Intravenous Immunoglobulin(IVIg) Therapy Distributors
  9. 9.2.3 Intravenous Immunoglobulin(IVIg) Therapy Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst